Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MNKD $0.78 0.0850 +12.22%
KPTI $10.12 0.3900 +4.01%
RXDX $5.80 0.2100 +3.76%
CASI $1.17 0.0400 +3.54%
ARGS $4.92 0.1389 +2.91%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

SPHS $2.94 -0.2800 -8.70%
MTP $3.95 -0.3500 -8.14%
NYMX $3.39 -0.2199 -6.09%
OMED $10.18 -0.6600 -6.09%
JUNO $29.78 -1.7500 -5.55%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

Long Hours of Sleep Up Cancer Risk

(Times of India/ANI) May 1, 2013 - A new study has found a significant positive association between long sleep duration and the development of colorectal cancer, especially among individuals who are overweight or snore regularly.
read article 

Women Smokers and Colon Cancer Risk

(WebMD/HealthDay News) Apr 30, 2013 - Smoking's connection to cancer is well-established. Now, researchers say cigarettes increase the odds for developing colon cancer, especially for women.
read article 

Mayo Clinic Finds Experimental Drug Inhibits Growth in All Stages of Common Kidney Cancer

(Mayo Clinic) Apr 30, 2013 - Researchers at Mayo Clinic's campus in Florida have discovered a protein that is overly active in every human sample of kidney cancer they examined.
read press release 

Diabetes Drug Makes Lung Cancer Vulnerable to Radiotherapy

(Cancer Research UK) May 1, 2013 - The diabetes drug metformin slows the growth of lung cancer cells and makes them more likely to be killed by radiotherapy, according to a study published in the British Journal of Cancer today.
read press release 

Chemo, Radiation, Then Surgery Improves Lung Cancer Survival

(University of Illinois at Chicago) Apr 30, 2013 - In one of the largest observational studies of its kind, researchers report that a combination of chemotherapy and radiation followed by surgery in patients with stage 3 non-small cell lung cancer improves survival.
read press release 

Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration

(Yahoo! Finance) May 1, 2013 - Janssen Research & Development, LLC announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and IMiD.
read article 

Regulatory Update: Trametinib US PDUFA Date Extended to 3 September 2013

(GlaxoSmithKline) May 1, 2013 - GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib, its MEK inhibitor, has been extended by 3 months to 3 September 2013.
read corporate press release 

Breast Implants May Harm Breast Cancer Survival Chances, Study Finds

(The Guardian) Apr 30, 2013 - Women with cosmetic breast implants who develop breast cancer may have a greater chance of dying of the disease than those without, according to a study.
read article 

How Much Do Financial Interests Sway Researchers?

(Reuters Health) Apr 30, 2013 - Funding from drug companies and other potential conflicts of interest did not influence the conclusions reached by researchers testing new cancer treatments over the past few years, according to a new analysis.
read article 

Regeneron Pharmaceuticals Co-Founder Receives $81.55 Million Compensation

(Fox Business/Dow Jones Newswires) Apr 29, 2013 - Regeneron Pharmaceuticals Inc.'s stock price tripled last year, and the compensation of co-founder and Chief Executive Leonard Schleifer nearly did, too.
read article 

Insider-Trading Probe Trains Lens on Boards

(Wall Street Journal) Apr 30, 2013 - Federal prosecutors launched a criminal investigation into whether corporate directors misused government-sanctioned trading plans to sell company shares for investment funds they run.
read article (paid subscription required) 

Consensus Builds For Universal HIV Testing

(NPR/Shots blog) Apr 30, 2013 - Everybody needs an HIV test, at least once. That's the verdict from the U.S. Preventive Services Task Force, which has just joined the Centers for Disease Control and Prevention and a scrum of professional medical societies in calling for universal testing for the virus that causes AIDS.
read article 

Letters: Physician Sunshine Act Doesn't Disclose All Incentives

(Wall Street Journal) Apr 30, 2013 - Kaiser Permanente's Robert Pearl is misleading the general public into thinking that a physician who partakes in a medical-education event at which a modest meal is provided is on the medical-device- or pharmaceutical-industry dole ("Medical Conflicts of Interest Are Dangerous," op-ed, April 24).
read article (paid subscription required) 

Europe's Regulator Digs In for Drug Data Fight

(Reuters) Apr 30, 2013 - The head of Europe's medicines regulator is digging in for a fight over data transparency after being stopped from releasing information on drugs from two U.S. companies by a court ruling.
read article 

Medicare Releases a 1,424-Page Rule That’s Actually Really Interesting!

(Washington Post/Wonkblog) Apr 29, 2013 - Medicare will pay hospitals more next year—and expects better quality in return.
read article (free registration required) 

Doctors Rush To Obamacare's Accountable Care Approach

(Forbes) Apr 27, 2013 - The number of physicians participating in the emerging medical care delivery system known as “accountable care organizations” (ACOs) has tripled as the health care industry moves further away from fee-for-service medicine.
read article 

Oh, Come On: Pharma Whinges About Government Drug Sales Force.

(Forbes) Apr 29, 2013 - The Daily Caller, the website founded and edited by libertarian Tucker Carlson, has found a new complaint among big pharma executives.
read article 

Behind the Cover Story: Peggy Orenstein on Rethinking Her Stance on Mammograms

(New York Times/The 6th Floor blog) Apr 29, 2013 - Peggy Orenstein, a contributing writer for the magazine, wrote this week’s cover article on the public-relations machine fueling breast-cancer awareness and what it means for patients’ health.
read article 

Send Congress a Message: You Fixed Flight Delays; Now Save Cancer Care

(COA) Apr 29, 2013 - Before Congress flew out of DC for a week, they passed a bill ordering the FAA to shift budgets around impacted by the sequester cut to end flight delays.
read article 

ASCO Notice: 2013 Breast Cancer Symposium

(ASCO) Apr 30, 2013 - 2013 Breast Cancer Symposium: Abstract Submission Deadline is May 7, at 11:59 PM (EDT).
read article 

CMS Updates EHR FAQs: Information on Sequestration and Attestation

(ACCC) Apr 25, 2013 - CMS had posted two updated FAQs related to the Medicare and Medicaid Electronic Health Record (EHR) Incentive Programs. FAQs include information on how EHR incentive payments will be affected by sequestration, as well as guidance on how to successfully attest following an EHR vendor transition.
read article 

Oncology Drug Shortages Affecting Care for Cancer Patients

(ASHP) Apr 24, 2013 - A new study of the effects of oncology drug shortages, published in the April 1 edition of the American Journal of Health-System Pharmacy (AJHP), reveals that cancer patients are paying a high price in terms of delayed and altered treatment.
read press release 

GTx Initiating Phase 2, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast Cancer

(GTx) Apr 30, 2013 - GTx, Inc., announced today that it is initiating a proof of concept, Phase 2, open-label clinical study to evaluate enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the potential treatment of metastatic breast cancer.
read corporate press release 

Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDS

(Yahoo! Finance) Apr 30, 2013 - Nearly doubles expected median survival of older patients With MDS who failed front-line therapies.
read article 

OncoGenex Announces that the Borealis-2(TM) Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is Now Open for Enrollment

(MarketWatch) Apr 30, 2013 - OncoGenex Pharmaceuticals, Inc. today announced initiation of the Borealis-2™ clinical trial, an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy treatment.
read article